Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA FE 1/20 vs OVCON-35
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years old who have reached menarche and desire contraception,Treatment of heavy menstrual bleeding in women without organic pathology
Prevention of pregnancy
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Ethinyl estradiol undergoes CYP3A4 metabolism and first-pass conjugation; norethindrone acetate is deacetylated to norethindrone, primarily metabolized by CYP3A4 and reduction pathways.
No dosage adjustment required for mild to moderate renal impairment. Contraindicated in patients with markedly impaired renal function due to potential fluid retention and estrogen-related adverse effects.
No dose adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use this product.
AUROVELA FE 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is associated with a slightly increased risk of congenital anomalies, including cardiovascular and limb defects. Second and third trimester exposure may cause fetal harm, including feminization of male fetuses and genitourinary abnormalities. No known risk of miscarriage.
FDA Pregnancy Category X. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: fetal feminization in males, vaginal adenosis in females, and other urogenital anomalies. Postnatal: increased risk of neurodevelopmental issues.
AUROVELA FE 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg with ferrous fumarate (iron) in the placebo pills. It is a monophasic oral contraceptive with low estrogen dose; consider for patients needing iron supplementation or those with heavy menstrual bleeding. The ferrous fumarate may cause gastrointestinal upset or dark stools. Breakthrough bleeding is more common with 20 mcg EE pills. Advise consistent dosing at the same time daily to maintain efficacy. Contraindicated in patients with migraine with aura, hypertension (>160/100), or history of thromboembolism. Monitor for signs of DVT/VTE, especially in smokers over 35.
OVCON-35 is a combined oral contraceptive (COC) containing norethindrone 0.4 mg and ethinyl estradiol 35 mcg. It has higher progestin dose relative to estrogen, making it suitable for women with estrogen-related side effects. Monitor for breakthrough bleeding, particularly in early cycles. Contraindicated in women with BMI > 35 due to increased thromboembolic risk. Consider interaction with CYP450 inducers (e.g., rifampin) which may reduce contraceptive efficacy. Use with caution in migraine with aura due to stroke risk.
No interactions on record
No interactions on record
AUROVELA FE 1/20 and OVCON-35 are distinct pharmacological agents. AUROVELA FE 1/20 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyTreatment of moderate acne vulgaris in females ≥15 years old who have reached menarche and desire contraceptionTreatment of heavy menstrual bleeding in women without organic pathology. OVCON-35 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. AUROVELA FE 1/20 carries a safety status of Category C, whereas OVCON-35 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized via reduction and sulfate conjugation, partly involving CYP3A4.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Norethindrone: ~61% bound to albumin and SHBG; ethinyl estradiol: ~97% bound to albumin.
Ethinyl estradiol: 97-98% (mainly albumin, SHBG); norethindrone: 90-95% (albumin, SHBG).
Norethindrone: ~2.7 L/kg; ethinyl estradiol: ~1.9 L/kg; distributes into breast milk.
Ethinyl estradiol: 2-4 L/kg; norethindrone: 4-6 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~64%; ethinyl estradiol ~45% (first-pass metabolism).
Ethinyl estradiol: ~38-48% (first-pass metabolism); norethindrone: ~64% (range 47-73%).
Contraindicated in patients with acute or chronic hepatic dysfunction, including Child-Pugh A, B, or C cirrhosis, due to impaired steroid metabolism.
Contraindicated in severe hepatic disease (Child-Pugh Class C) and active liver disease. Use with caution in Child-Pugh Class A or B; dose adjustment not established.
Post-menarche: same as adult dosing (one tablet daily for 21 days, then iron tablet for 7 days). Not indicated before menarche.
Safety and efficacy not established in children under 18 years. Postmenarchal adolescents: same as adult dosing, but weigh risks vs. benefits.
Not indicated for use after menopause. No specific dose adjustment; use lowest effective dose if considered for other indications, but generally avoid due to increased risk of thromboembolism and cardiovascular events.
Not typically used in postmenopausal women. Contraindicated in women over 60 due to increased risk of thromboembolic events and hypertension.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use combination oral contraceptives.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Risk of hepatic neoplasia. Elevated blood pressure. Gallbladder disease. Carbohydrate and lipid effects. Headache. Uterine bleeding irregularities. Discontinue if jaundice, vision loss, or thromboembolic symptoms occur.
Thrombophlebitis or thromboembolic disorders. History of DVT/PE. Cerebrovascular or coronary artery disease. Known or suspected breast cancer. Estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Known or suspected pregnancy. Active liver disease or hepatic adenoma. Hypersensitivity to components. Smokers >35 years.
No significant food interactions. Avoid grapefruit juice as it may increase estrogen levels. Ferrous fumarate absorption is enhanced by vitamin C (e.g., citrus) and decreased by calcium supplements or dairy; take iron tablets separately from high-calcium meals if concerned. Alcohol is not contraindicated but may increase risk of liver toxicity in high doses; limit consumption.
No specific food interactions. However, grapefruit juice may increase ethinyl estradiol levels by inhibiting CYP3A4; avoid excessive consumption. Cranberry juice may increase warfarin effect if taken concurrently, but no direct interaction with OVCON-35. Take with food or milk to reduce nausea.
Small amounts of contraceptive steroids and/or metabolites are excreted in breast milk. Milk-to-plasma (M/P) ratio: not established. Use may reduce milk production and composition; if possible, use alternative contraception. AAP considers it compatible with breastfeeding but caution advised.
Contraindicated in breastfeeding. Estrogens and progestins are excreted in breast milk. M/P ratio not established. May reduce milk production and quality.
No dose adjustment is indicated as the drug is contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered hepatic metabolism) may require dose adjustment if inadvertently used, but no established recommendations.
Contraindicated in pregnancy; no dose adjustment applies. Use is contraindicated once pregnancy is confirmed. Discontinue immediately.
Take one tablet daily at the same time, with or without food.,If you miss a pill, refer to the package leaflet or consult your provider; for missing active pills, take the missed pill as soon as remembered and use backup contraception for 7 days.,The last 7 pills (brown) are iron tablets and should be taken even if you don't have a period; they do not prevent pregnancy.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially during the first few cycles.,This pill does not protect against HIV or other sexually transmitted infections; use condoms for STD prevention.,Avoid smoking, especially if over 35, due to increased risk of blood clots.,Ferrous fumarate may cause dark or greenish stools; this is harmless.,Contact your doctor immediately if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes.
Take one tablet daily at the same time to maintain hormone levels and prevent pregnancy.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding. These often improve after 2-3 cycles.,This medication does not protect against sexually transmitted infections (STIs). Use barrier protection.,Inform your doctor of all medications, especially antibiotics, anticonvulsants, or St. John's Wort, as they may reduce effectiveness.,Seek immediate medical attention if you experience severe leg pain, chest pain, sudden shortness of breath, or severe headache (signs of blood clots or stroke).,Do not smoke while using this medication, especially if over 35 years old; smoking increases risk of serious cardiovascular side effects.